AnaptysBio, Inc. (NASDAQ:ANAB) Stock Has Average Price Target of $79.85

by · The Markets Daily

Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $79.15.

A number of equities research analysts recently weighed in on ANAB shares. TD Cowen lowered their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Zacks Research cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 price target on the stock. in a report on Tuesday, August 25th. HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of AnaptysBio in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th.

Get Our Latest Research Report on AnaptysBio

AnaptysBio Stock Down 1.4%

Shares of NASDAQ ANAB opened at $51.00 on Wednesday. The firm has a market capitalization of $1.52 billion, a P/E ratio of 9.50 and a beta of 0.71. The stock’s 50-day simple moving average is $55.38 and its two-hundred day simple moving average is $59.09. AnaptysBio has a twelve month low of $13.86 and a twelve month high of $72.36.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $5.57. The firm had revenue of $27.49 million for the quarter, compared to analysts’ expectations of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.During the same quarter last year, the firm posted ($1.30) EPS. As a group, research analysts anticipate that AnaptysBio will post -1.48 EPS for the current fiscal year.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC lifted its stake in AnaptysBio by 2.9% during the second quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock worth $39,285,000 after purchasing an additional 16,573 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of AnaptysBio by 21.2% during the 2nd quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock valued at $21,900,000 after purchasing an additional 56,743 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of AnaptysBio by 13.5% during the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock valued at $295,000 after buying an additional 518 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of AnaptysBio during the 2nd quarter valued at about $1,164,000. Finally, Irenic Capital Management LP purchased a new position in shares of AnaptysBio during the 2nd quarter valued at about $4,755,000.

About AnaptysBio

(Get Free Report)

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.

Featured Stories